Article
Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.
Archives of pathology & laboratory medicine - 1 Jun 2013
Harbison Christopher T, Horak Christine E, Ledeine Jean-Marie, Mukhopadhyay Pralay, Malone Daniel P, O'Callaghan Chris, Jonker Derek J, Karapetis Christos S, Khambata-Ford Shirin, Gustafson Nancy, Trifan Ovidiu C, Chang Shao-Chun, Ravetto Paul, Iv George A Green
Abstract excerpt
CONTEXT: The therascreen KRAS RGQ polymerase chain reaction kit is being developed as a companion diagnostic to aid clinicians, through detection of KRAS mutations, in the identification of patients with metastatic colorectal cancer (mCRC) who are more likely to benefit from cetuximab. OBJECTIVES: To assess whether KRAS mutation status, determined by using the therascreen KRAS kit, is a predictive marker of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.